---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-036440"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T18:53:22.391756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025

## Summary
- Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.
- Cash at June 30, 2023 was $168.7M, down from $215.5M at Dec 31, 2022; expected to fund operations into 2025.
- Phase 2 potentially registrational BA3011 UPS study continues enrolling; FDA meeting request submitted for NSCLC study.
- CAB-CTLA-4 BA3071 cleared fifth cohort (5 mg/kg) with no DLTs; sixth cohort enrolling; Phase 1 data readout on track for 2H23.
- Anticipated data across BA3021 NSCLC, melanoma, SCCHN to enable 'go' decision for indications in 2H23.

## SEC filing metadata
- accession: 0000950170-23-036440
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/0000950170-23-036440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/bcab-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-036440
- JSON: https://secwatch.observer/filing/0000950170-23-036440.json
- Plain text: https://secwatch.observer/filing/0000950170-23-036440.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa
  - Result: reported results
  source text: Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/0000950170-23-036440-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.